Medicilon and Hengrui Pharma Amplify Partnership To Revolutionize ADCs, Small Nucleic Acids, And CGT Drugs

Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") have recently entered into a strategic partnership. Their collaboration will center on the preclinical assessment of novel drug types, specifically ADCs (antibody-drug conjugates), small nucleic acids, and cell and gene therapy (CGT) drugs. This alliance aims to propel innovation within the Chinese pharmaceutical sector, enhancing its global competitiveness.

The strengthened partnership between Medicilon and Hengrui Pharma is rooted in a longstanding relationship built on trust and experience. By merging Medicilon's preclinical research and development capabilities with Hengrui Pharma's innovative approaches and market presence, the two organizations aim to achieve significant advancements. Medicilon will utilize its expertise in drug discovery and development to offer Hengrui Pharma comprehensive preclinical services, including efficacy testing, pharmacokinetics, and toxicology studies for new drug types. Together, Medicilon and Hengrui Pharma are poised to drive groundbreaking progress in pharmaceutical therapies.

The exchange took place in a lively and friendly atmosphere as Hengrui Pharma's Vice General Manager and Global R&D President, Lianshan Zhang, along with other executives, toured Medicilon's Pudong Chuansha Park. They received a warm welcome from Medicilon's CEO, Chunlin Chen, and key members of the team. During the visit, Medicilon's R&D Team showcased their comprehensive preclinical services platform for pharmaceutical research and development. They emphasized Medicilon's expertise and technological strengths in safety evaluation, pharmacology, and pharmacokinetics, with a particular focus on PROTAC, ADC, nucleic acids, bispecific antibodies, peptides, vaccines, and cell and gene therapy (CGT).

Hengrui Pharma's Vice General Manager & Global R&D President Lianshan Zhang mentioned, "Medicilon possesses robust innovation capabilities and service quality in this field, making it a trusted CRO partner. The collaboration between Hengrui Pharma and Medicilon not only acknowledges past achievements but also represents a deep exploration of future collaboration potential and forward-looking strategic planning."

Medicilon's Founder & CEO Chunlin Chen expressed his opinion by saying, "Medicilon and Hengrui Pharma firmly believe that, through close collaboration, the process of drug R&D will be accelerated in the future, contributing to the innovative development of the global pharmaceutical industry.”